Core Viewpoint - The A-share market is experiencing a bullish trend, driven by sectors such as innovative drugs, rare earth permanent magnets, solid-state batteries, and digital currencies, while gold and liquor sectors are underperforming [1][2]. Market Performance - As of June 9, the Shanghai Composite Index rose by 0.23% to 6393.26, the Shenzhen Component Index increased by 0.62%, and the ChiNext Index gained 1.22% [1][2]. - Notable sector performances include: - Weight loss drugs: +4.79% - CRO concept: +4.73% - Chemical pharmaceuticals: +4.34% - Innovative drugs: +4.17% - Alzheimer's concept: +3.81% - Medical services: +3.58% - Gold concept: -0.49% [2]. Institutional Insights - Market expectations are optimistic due to factors such as accelerated special bond issuance, support for industrial upgrades, and loose liquidity, suggesting a continued upward trend in June [3]. - A resistance zone is identified between 3391-3400 points, with a need for trading volume to exceed 1.3 trillion for a breakout [3][4]. - Recommended sector allocations include autonomous controllable fields, especially with upcoming global AI technology and solid-state battery summits, and defensive biopharmaceuticals for opportunistic buying [4].

Core Viewpoint - Despite external negative disturbances, internal support forces are strong, limiting the downward space of stock indices, with a high probability of short-term index fluctuations [5] Group 1: Market Trends - The solid-state battery sector is gaining strength, with companies like Yinglian Co. and Dexin Technology hitting the daily limit [2] - The CRO sector in pharmaceuticals is also performing well, with companies like Lianhua Technology reaching the daily limit [5] - The agricultural pesticide sector continues its strong performance, with Changqing Co. achieving consecutive gains [5] Group 2: Institutional Insights - CITIC Securities suggests avoiding macro disturbances and focusing on industrial trends, indicating a transitional phase before a potential bull market in the third to fourth quarter [3] - CITIC Jiantou emphasizes the importance of tracking capital flows and industry sentiment in June, a key period for dividend distribution, to identify high-dividend investment opportunities [4]

A股CRO概念板块震荡走强，睿智医药涨超17%，联化科技封板涨停，美诺华涨超9%，金凯生科、圣诺 生物、万邦医药、皓元医药等跟涨。 订阅A股市场资讯 +订阅 ...

Group 1 - The CRO concept sector has seen a significant rise, with companies like Lianhua Technology (002250) hitting the daily limit up, indicating strong investor interest [1] - Ruizhi Pharmaceutical (300149) has increased by over 10%, reflecting positive market sentiment towards the CRO sector [1] - Other companies such as Meinuohua (603538), Jinkai Biotechnology (301509), Shengnuo Biotech, Wanbang Pharmaceutical (301520), and Haoyuan Pharmaceutical have also experienced gains, showcasing a broader trend in the industry [1]

Core Viewpoint - The market experienced a rebound with the ChiNext Index leading the gains, reflecting a mixed performance across various sectors and stocks [1] Group 1: Market Performance - The total trading volume in the Shanghai and Shenzhen markets reached 1.29 trillion, an increase of 137.4 billion compared to the previous trading day [1] - The ChiNext Index rose by 1.17%, while the Shanghai Composite Index increased by 0.23% and the Shenzhen Component Index rose by 0.58% [1] Group 2: Sector Performance - The computing power concept stocks saw a collective rebound, with CPO and other related sectors leading the gains, and Shenghong Technology reaching a historical high [1] - Stablecoin concept stocks showed strong performance, with Cuiwei Co., Ltd. hitting the daily limit [1] - Virtual power plant concept stocks were active, with Zhongdian Xinlong and others reaching the daily limit [1] - Consumer stocks experienced a collective adjustment, with Chao Hong Ji hitting the daily limit down [1] Group 3: Sector Gains and Losses - The sectors with the highest gains included CPO, football concept, power IoT, and stablecoin concepts [1] - The sectors with the largest declines included beauty care, food processing, beverage manufacturing, and CRO [1]

Group 1 - The US government is pressuring countries to submit their best trade negotiation proposals by June 4, including tariffs and quotas for purchasing US agricultural products, or face punitive measures [1] - The Chinese government is tightening controls to prevent illegal outflow of strategic minerals, with various provinces enhancing regulatory measures [2] - The weakening of the US dollar is becoming a consensus among Wall Street banks, with the ICE dollar index down 8.9% year-to-date, leading to a rise in gold prices [3] Group 2 - Circle, a major stablecoin company, is set to go public on June 5, marking the first IPO in the stablecoin sector, which has positively impacted related stocks [4] - The Chinese government has issued new policies to improve the electricity service environment, which is expected to lower costs for small private enterprises and benefit power equipment companies [7] - Pharmaron, a leading CRO, is expanding its reach into overseas markets by investing in a healthcare fund, with a significant increase in revenue and new orders reported [8][10]

Market Overview - The Asia-Pacific markets collectively declined, with the Nikkei 225 and the Korea Composite Index dropping nearly 1%, and the Hang Seng Index falling by 1.5% during intraday trading [1] - The A-share market also saw all three major indices decline, with several high-priced stocks like Wangzi New Materials and Yong'an Pharmaceutical hitting the daily limit down [2] High-priced Stocks Plummet - High-priced stocks experienced significant drops, with Wangzi New Materials hitting the daily limit down at a price of 19.67 CNY per share, reflecting a decline of 9.98% [4][5] - Yong'an Pharmaceutical also faced a daily limit down, citing a significant deviation from its fundamentals and warning of high speculation risks [7] - Other high-priced stocks such as Shangwa Co., Guofang Group, and others also reported substantial declines [13] Innovation Drug Sector Strengthens - The pharmaceutical sector, particularly innovative drugs, saw a strong performance, with companies like Ruizhi Pharmaceutical and Nuo Si Lan De rising over 15% [15] - The National Medical Products Administration recently approved 11 new drug listings, covering various therapeutic areas, which has contributed to the positive sentiment in the sector [19] - Analysts believe that the pharmaceutical sector is supported by four key factors: ongoing demand for healthcare, increasing global competitiveness of domestic innovative drugs, signs of profit reversal, and low valuations in the innovative drug sector [20][21] Livestock Sector Leads Gains - The livestock sector led the market gains, with pig and chicken farming concepts showing the highest increases, including stocks like Juxing Agriculture and Xiangjia Co. hitting the daily limit up [23] - Recent legislative efforts in Shanghai and Sichuan aim to support the development of the livestock industry, which may further bolster the sector [26]

A股CRO概念股午后走强，昭衍新药涨停，睿智医药、联化科技此前封板，美迪西涨超10%，凯莱英、 康龙化成、诺思格、药明康德等跟涨。 ...

A股CRO概念持续拉升，睿智医药涨停，美迪西涨超8%，成都先导涨近7%，联化科技、凯莱英等跟 涨。 ...

A股午评：三大股指早盘窄幅震荡 可控核聚变板块表现强势 金十数据5月28日讯，A股三大指数早盘区间窄幅震荡盘整，收盘涨跌不一，截止午盘收盘，沪指涨 0.07%，深成指跌0.04%，创业板指涨0.02%，北证50指数跌0.14%。板块题材上，可控核聚变持续活 跃，乳业、饮料制造板块冲高回落，互联网电商、CRO概念跌幅居前。两市近3300只个股下跌，半日 成交额超6500亿元。 ...